Amitriptyline, Topiramate Don't Cut Pediatric Migraine vs Placebo

This article originally appeared here.
Share this content:
Amitriptyline, Topiramate Don't Cut Pediatric Migraine vs Placebo
Amitriptyline, Topiramate Don't Cut Pediatric Migraine vs Placebo

THURSDAY, Oct. 27, 2016 (HealthDay News) -- For children and adolescents with migraine, amitriptyline and topiramate do not reduce headache frequency or headache-related disability more than placebo, according to a study published online Oct. 27 in the New England Journal of Medicine. The research was published to coincide with the annual meeting of the Child Neurology Society, held from Oct. 26 to 29 in Vancouver, Canada.

Scott W. Powers, Ph.D., from the University of Cincinnati College of Medicine, and colleagues conducted a randomized trial in children and adolescents (age 8 to 17 years) with migraine. Patients were randomly allocated to receive amitriptyline, topiramate, and placebo in a 2:2:1 ratio (132, 130, and 66 patients, respectively).

The researchers observed no significant differences between the groups in the primary outcome of a relative reduction of 50 percent or more in the number of headache days in the comparison of the 28-day baseline period with the last 28 days of the 24-week trial. No significant differences were seen between the groups in headache-related disability, headache days, or the percentage of patients completing the 24-week treatment period. Higher rates of several adverse events were seen for patients who received amitriptyline or topiramate versus placebo.

"There were no significant differences in reduction in headache frequency or headache-related disability in childhood and adolescent migraine with amitriptyline, topiramate, or placebo over a period of 24 weeks," the authors write.

Abstract
Full Text
More Information

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

FDA Approves Kinase Inhibitor for Treatment of AML

FDA Approves Kinase Inhibitor for Treatment of AML

Midostaurin, in combination with chemotherapy, treats acute myeloid leukemia in adults

Enzyme Replacement Drug OK'd for Form of Batten Disease

Enzyme Replacement Drug OK'd for Form of Batten ...

Brineura will be used to treat children with late infantile neuronal ceroid lipofuscinosis type 2 Batten

is free, fast, and customized just for you!

Already a member?

Sign In Now »